KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.85

Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study.

Andrew J Wagner, William D Tap, Sebastian Bauer, Jean-Yves Blay, Jayesh Desai, Hans Gelderblom, Emanuela Palmerini, Christopher W Ryan, Charles Peterfy, John H Healey, Michiel van de Sande, Meng Qian, Dale E Shuster, Abdul Rajper, Xin Ye, Kristen Tecson, Margaret J Wooddell, Silvia Stacchiotti

Oncologist 30(7) oyae345

PMID40613752
PMCIDPMC12231594
DOI10.1093/oncolo/oyae345
发表日期2025-07-04
入排依据:The study is a Phase III randomized trial with drug intervention and primary results, but the primary/key secondary efficacy endpoints reported (ORR, DOR) are not time-to-event endpoints as defined by the criteria. No Kaplan-Meier or HR analysis is indicated in the abstract.
已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。
摘要

摘要

BACKGROUND: Pexidartinib is approved in the US, Taiwan, and Korea for adults with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery based on the phase III ENLIVEN study (NCT02371369). We report the final long-term efficacy and safety results from ENLIVEN. METHODS: Adults with symptomatic TGCT not eligible for surgery were enrolled and randomized to pexidartinib or placebo (part 1). The blinded phase (part 1) ended at week 25; patients received pexidartinib (800 mg/day) until progression, toxicity, or study completion (part 2). This analysis includes patients who received pexidartinib at any time during ENLIVEN. Centrally reviewed overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and tumor volume score (TVS), time to response, duration of response (DOR), patient-reported outcomes (PROs), and long-term safety were assessed. RESULTS: Overall, 91 patients received pexidartinib. With a median follow-up of 31.2 (range: 2-66) months, ORR was 60.4% and 68.1% by RECIST and TVS, respectively. Median DOR by RECIST was not reached (range: 0.03-63.4 months). Most responses were within the first 6 months of treatment; most responders were on 800 mg vs 600/400 mg dose levels, respectively. Throughout parts 1 and 2, 3 (3%) patients had progressive disease per RECIST without dose reduction/interruption. PROs improved or were maintained. The most common grade 3/4 treatment-emergent adverse events were aspartate aminotransferase (AST) increase (9%), alanine aminotransferase (ALT) increase (10%), and hypertension (8%). Twenty-eight (31%) patients had AST or ALT ≥3 times the upper limit of normal (ULN); 17 (19%) patients had AST or ALT ≥5 times the ULN. No new safety signals were observed after long-term pexidartinib treatment. CONCLUSIONS: Final long-term ENLIVEN results demonstrated that pexidartinib sustained clinical benefit, with increased ORR by RECIST and TVS compared to the end of the blinded phase at week 25. No new safety signals were reported.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Patient flow through parts 1 and 2 of ENLIVEN. *After urgent safety measure. † 15 patients discontinued after the urgent safety measure; 1 discontinued prior to the urgent safety measure.
非 KM Figure
Figure 2Figure 2. Tumor responses for the March 2017, January 2018, and April 2021 data cutoffs. Abbreviations: SD, standard deviation.
非 KM Figure
Figure 3Figure 3. Time to response for part 1, part 2, and all pexidartinib-treated patients per (A) RECIST v1.1 and (B) TVS. Abbreviations: RECIST, Response Evaluation Criteria in Solid Tumors; TVS, tumor volume score.
非 KM Figure